A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT07244263. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can also burst. Over time, the area can get scars and tunnels on or under the skin. Recent studies suggest that the condition may start when hair follicles become damaged and blocked. This impacts the skin and may activate the body's germ-fighting (immune) system. This allows bacteria to grow on the skin which worsens the condition and can cause abscesses. The main aims of this study are to learn how safe zasocitinib is, how well it works and how well adults with HS tolerate it compared with a placebo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks). During the study, participants will visit their study clinic 12 times.
Study identification
- NCT ID
- NCT07244263
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 25, 2026
- Primary completion
- Feb 21, 2028
- Completion
- Feb 21, 2028
- Last update posted
- Mar 5, 2026
2026 – 2028
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Scottsdale | Arizona | 85259 | Not yet recruiting |
| Johnson Dermatology | Fort Smith | Arkansas | 72916 | Recruiting |
| First OC Dermatology Research | Fountain Valley | California | 92708 | Recruiting |
| Direct Helpers Research Center | Hialeah | Florida | 33012 | Not yet recruiting |
| Advanced Clinical Research Institute | Tampa | Florida | 33607 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Not yet recruiting |
| Wayne State University | Detroit | Michigan | 48201 | Not yet recruiting |
| Hamzavi Dermatology | Fort Gratiot | Michigan | 48059 | Recruiting |
| StracSkin, PLLC | Greenland | New Hampshire | 03840 | Recruiting |
| Northwell Health Physician Partners | Lake Success | New York | 11020 | Not yet recruiting |
| Mount Sinai Doctors | New York | New York | 10028 | Not yet recruiting |
| Apex Clinical Research Center, LLC. | Mayfield Heights | Ohio | 44124 | Not yet recruiting |
| ODRC Enterprises, LLC dba Oregon Dermatology and Research Center | Portland | Oregon | 97210 | Not yet recruiting |
| Arlington Research Center, Inc. | Arlington | Texas | 76011 | Not yet recruiting |
| Texas Dermatology Research Center | Dallas | Texas | 75246 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07244263, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07244263 live on ClinicalTrials.gov.